Envoy Medical gets Nasdaq extension to regain $1 minimum bid compliance

• Envoy Medical received a Nasdaq notice that its Class A common stock is not in compliance with the $1 minimum bid price rule for continued listing on the Nasdaq Capital Market.
• Nasdaq granted a second 180-day compliance period through Nov. 16, 2026, to regain compliance.
• The stock must close at or above $1 for at least 10 consecutive business days to cure the deficiency.
• Nasdaq eligibility for the extension was based on meeting other continued listing standards, with the company indicating it may pursue a reverse stock split if needed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Envoy Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-060556), on May 22, 2026, and is solely responsible for the information contained therein.